Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy.

MLA

Gomes da Cunha, Juliana Pierobon, et al. “Validation of the Residual Cancer Burden Index as a Prognostic Tool in Women with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy.” Journal of Clinical Pathology, vol. 76, no. 4, Apr. 2023, pp. 239–43. EBSCOhost, https://doi.org/10.1136/jclinpath-2021-207771.

APA

Gomes da Cunha, J. P., Goncalves, R., Silva, F., Aguiar, F. N., Mota, B. S., Chequim, B. B., Soares, J. M., Baracat, E. C., & Filassi, J. R. (2023). Validation of the Residual Cancer Burden Index as a prognostic tool in women with locally advanced breast cancer treated with neoadjuvant chemotherapy. Journal of Clinical Pathology, 76(4), 239–243. https://doi.org/10.1136/jclinpath-2021-207771

Chicago

Gomes da Cunha, Juliana Pierobon, Rodrigo Goncalves, Fernando Silva, Fernando Nalesso Aguiar, Bruna Salani Mota, Bruna Bello Chequim, José Maria Soares, Edmund C Baracat, and José Roberto Filassi. 2023. “Validation of the Residual Cancer Burden Index as a Prognostic Tool in Women with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy.” Journal of Clinical Pathology 76 (4): 239–43. doi:10.1136/jclinpath-2021-207771.